gland pharma glp-1 manufacturing reported a strong December quarter with 22.5% revenue growth and 27% YoY profit growth, driven by healthy performance across the US, India, and Europe. The stock reacted positively, gaining over Schematic representation of production of

A study in ( JAMA Ophthalmology (June 5, 2025) reported that people with type-2 diabetes using GLP-1 receptor agonists appear to have a higher risk of neovascular age-related macular degeneration (AMD) the wet form of the disease

And globally, the market is expected to expand at a similar pace

Nausea is typically most pronounced during dose escalation and often improves with continued use as physiological tolerance develops

** Daily Value (DV) not established Always Happy Promise: Don't like a product

Conclusion Constipation on GLP1 medications is common, persistent, and driven by the same slowed gut motility that helps reduce appetite

As your body adjusts to the medication and your nutrition improves, fatigue usually fades within a few weeks